Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Besides osteogenesis imperfecta, several genetic diseases may cause alterations in bone metabolism, with low bone mass, low bone strength, and fragility fractures. Some other diseases are instead characterized by bone formation outside the skeletal system (heterotopic ossification). Although little data are available, and mainly from case reports and not from controlled studies on significantly large samples, bisphosphonates seem to be effective to increase bone mass, reduce the risk of fractures, alleviate bone pain, and even, in some measure, hinder the formation of heterotopic bone. Only for the more common diseases, like Duchenne muscular dystrophy and cystic fibrosis, there are sufficient data to recommend the prudent use of BPs as a standard treatment of bone complications.

Original languageEnglish
Title of host publicationBone Drugs in Pediatrics: Efficacy and Challenges
PublisherSpringer US
Pages81-99
Number of pages19
ISBN (Print)9781489974365, 1489974350, 9781489974358
DOIs
Publication statusPublished - Feb 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta'. Together they form a unique fingerprint.

  • Cite this

    Bianchi, M. L. (2014). Use of bisphosphonates in genetic diseases other than osteogenesis imperfecta. In Bone Drugs in Pediatrics: Efficacy and Challenges (pp. 81-99). Springer US. https://doi.org/10.1007/978-1-4899-7436-5_6